RxDoctor Payments Data

Karl Trippe, MD

Family Medicine · Waco, TXNPI 1285615674

Payments from drug & device makers

$11,779in general payments, 2019–2025

Across 743 payments — averaging $15.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$1K
  • Lilly USA, LLC$1K
  • Kowa Pharmaceuticals America, Inc.$1000
  • GSK$646
  • Amarin Pharma, Inc.$618
  • plus $6K from 47 others

What the payments were for

  • Food & beverage$11,728100%
  • Education$510%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,779 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$203,510
Medicare patients
301
Services billed
4,811

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide108$129,979
TrulicityDulaglutide72$86,072
MounjaroTirzepatide67$77,023
JardianceEmpagliflozin73$70,840
EliquisApixaban65$63,311
NuplazidPimavanserin Tartrate11$54,253
XareltoRivaroxaban35$40,463
MyrbetriqMirabegron41$40,243
JanuviaSitagliptin Phosphate53$38,565
FarxigaDapagliflozin Propanediol30$30,827
VascepaIcosapent Ethyl20$19,048
LinzessLinaclotide22$18,254
JanumetSitagliptin Phos/Metformin Hcl15$12,989
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$12,847
Spiriva HandihalerTiotropium Bromide13$12,594

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$1,088$163,095139 claims
Novo NordiskOzempic$1,508$129,979108 claims
Boehringer IngelheimJardiance, Jentadueto$405$76,61984 claims
PfizerEliquis, Premarin$612$66,90576 claims
MerckJanuvia, Janumet$383$51,55368 claims
Johnson & JohnsonXarelto$184$40,46335 claims
Astellas Pharma US IncMyrbetriq$125$40,24341 claims
AstraZenecaFarxiga, Symbicort$526$36,44154 claims
GSKTrelegy Ellipta, Incruse Ellipta, Anoro Ellipta$646$28,25253 claims
AbbVieLinzess$1,144$18,25422 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$72$4,116423 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Waco

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →